与低密度脂蛋白受体结合的阿波脂蛋白B100的结构
Mart Reimund1, Altaira D Dearborn2, Giorgio Graziano1
1Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Nature
|December 11, 2024
概括
对阿波利波蛋白B100 (apoB100) 和LDL受体 (LDLR) 相互作用的结构洞察力揭示了突变如何导致家族高胆固醇血症,为心血管疾病治疗提供了点.
科学领域:
- 结构生物学
- 生物化学
- 心血管研究
背景情况:
- 脂蛋白B100 (apoB100) 对于低密度脂蛋白 (LDL) 的结构和LDLR结合至关重要.
- 在apoB100或LDLR的突变导致家族高胆固醇,增加心血管疾病的风险.
- apoB100-LDLR相互作用的结构基础在很大程度上是未知的.
研究的目的:
- 阐明LDL与LDLR结合的apoB100的高分辨率结构.
- 了解LDL-LDLR相互作用的分子机制及其在家族高胆固醇血症中的作用.
主要方法:
- 使用冷电子显微镜 (cryo-EM) 来确定复杂的结构.
- 使用本地精细化来实现高分辨率的交互接口.
- 分析与家族高胆固醇血症相关的突变部位.
主要成果:
- 解决了两个关键的apoB100-LDLR绑定接口的详细结构.
- 一个接口涉及LDLR连结模块和apoB100的β带.
- 第二个接口将LDLR的β-螺旋域与apoB100的N端连接起来.
- 确定了这些接口如何调解LDL二元形成和LDLR结构变化.
- 在apoB100和LDLR中与疾病相关的突变位于LDL-LDLR界面.
结论:
- 提供前所未有的结构细节的apoB100-LDLR复合体.
- 解释了家族性高胆固醇血症中LDL结合和潜在的LDLR功能障碍的结构基础.
- 强调LDL-LDLR接口作为理解和潜在治疗高胆固醇症的关键部位.
相关概念视频
01:39Receptor-mediated Endocytosis
104.0K
Overview
104.0K
01:29Drug Distribution: Plasma Protein Binding
4.9K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
4.9K
01:30Drug Binding to Blood Components
110
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
110
01:45Regulation of Nuclear Protein Sorting
2.4K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
00:59COP Coated Vesicles
7.7K
Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of...
7.7K
01:12Clathrin Coated Vesicles
6.8K
Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
6.8K